Advertisement
Screener

MYRIAD GENETICS, INC. (MYGN) Capital Expenditures Incurred but Not yet Paid

MYRIAD GENETICS, INC. Capital Expenditures Incurred but Not yet Paid

MYRIAD GENETICS, INC. (MYGN) reported Capital Expenditures Incurred but Not yet Paid of $8.30 million for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-07.

Discontinued › Cash Flow › Other Cash Flow Items

us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2023-11-07

  • MYRIAD GENETICS, INC. capital expenditures incurred but not yet paid for the quarter ending 2023-09-30 was $800.00K.
  • MYRIAD GENETICS, INC. capital expenditures incurred but not yet paid for the quarter ending 2023-06-30 was -$500.00K, a 114.71% decline year-over-year.
  • MYRIAD GENETICS, INC. capital expenditures incurred but not yet paid for the quarter ending 2023-03-31 was $8.00M, a 788.89% increase year-over-year.
  • MYRIAD GENETICS, INC. capital expenditures incurred but not yet paid for the quarter ending 2022-12-31 was $5.70M.
  • MYRIAD GENETICS, INC. capital expenditures incurred but not yet paid for fiscal 2022 was $10.00M.
  • MYRIAD GENETICS, INC. capital expenditures incurred but not yet paid for fiscal 2021 was $0.00.
  • MYRIAD GENETICS, INC. capital expenditures incurred but not yet paid for fiscal 2020 was $0.00.
Period endCapital Expenditures Incurred but Not yet Paid 3 monthCapital Expenditures Incurred but Not yet Paid 6 monthCapital Expenditures Incurred but Not yet Paid 9 monthCapital Expenditures Incurred but Not yet Paid 12 month
2023-09-30$800.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07
$300.00K
derived: sum of 2 quarters · filed 2023-11-07
$8.30M
10-Q · filed 2023-11-07
$14.00M
derived: sum of 4 quarters · filed 2023-11-07
2023-06-30-$500.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04
$7.50M
10-Q · filed 2023-08-04
$13.20M
derived: sum of 3 quarters · filed 2023-08-04
$13.20M
derived: sum of 4 quarters · filed 2023-11-07
2023-03-31$8.00M
10-Q · filed 2023-05-04
$13.70M
derived: sum of 2 quarters · filed 2023-05-04
$13.70M
derived: sum of 3 quarters · filed 2023-11-07
$17.10M
derived: sum of 4 quarters · filed 2023-11-07
2022-12-31$5.70M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01
$5.70M
derived: sum of 2 quarters · filed 2023-11-07
$9.10M
derived: sum of 3 quarters · filed 2023-11-07
$10.00M
10-K · filed 2023-03-01
2022-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07
$3.40M
derived: sum of 2 quarters · filed 2023-11-07
$4.30M
10-Q · filed 2023-11-07
$4.30M
derived: sum of 4 quarters · filed 2023-11-07
2022-06-30$3.40M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04
$4.30M
10-Q · filed 2023-08-04
$4.30M
derived: sum of 3 quarters · filed 2023-08-04
$4.30M
derived: sum of 4 quarters · filed 2023-08-04
2022-03-31$900.00K
10-Q · filed 2023-05-04
$900.00K
derived: sum of 2 quarters · filed 2023-05-04
$900.00K
derived: sum of 3 quarters · filed 2023-05-04
$900.00K
derived: sum of 4 quarters · filed 2023-05-04
2021-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01
$0.00
derived: sum of 2 quarters · filed 2023-03-01
$0.00
derived: sum of 3 quarters · filed 2023-03-01
$0.00
10-K · filed 2023-03-01
2021-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02
$0.00
derived: sum of 2 quarters · filed 2022-11-02
$0.00
10-Q · filed 2022-11-02
2021-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-05
$0.00
10-Q · filed 2022-08-05
2021-03-31$0.00
10-Q · filed 2022-05-06
2020-12-31$0.00
10-K · filed 2023-03-01
2020-06-30$0.00
10-K · filed 2023-03-01

Similar stocks

Stock NameCountryMarket CapPE Ratio
Alpha Teknova, Inc. (TKNO)United States$0.500B-18.12
Insight Molecular Diagnostics Inc. (IMDX)United States$0.129B-3.90
IMMUCELL CORP /DE/ (ICCC)United States$0.091B116.10
QuidelOrtho Corp (QDEL)United States$0.733B-0.90
BIOMERICA INC (BMRA)United States$0.011B
Q/C TECHNOLOGIES, INC. (QCLS)United States$0.008B-1.93
Cardio Diagnostics Holdings, Inc. (CDIO)United States$0.006B
VOLITIONRX LTD (VNRX)$0.003B-0.64
ACHIEVE LIFE SCIENCES, INC. (ACHV)United States$0.806B-5.88
Intellia Therapeutics, Inc. (NTLA)United States$1.705B-5.92